Literature DB >> 10791918

Fibroblast growth factor receptor-4 splice variants cause deletion of a critical tyrosine.

W R van Heumen1, C Claxton, J O Pickles.   

Abstract

We have identified two novel isoforms of fibroblast growth factor receptor-4 (FGFR4). They result from alternative splicing of intron 17. Two transcripts, both slightly larger than the one coding for the known mouse FGFR4, are generated. The shortest (FGFR4-17a) includes the 31-most 3'-nucleotides of intron 17; the longest (FGFR4-17b) includes all 114 nucleotides of intron 17. Translation of the FGFR4-17a and FGFR4-17b splice variants predicts that both novel putative FGFR4 isoforms have a truncated C-terminal intracellular tail. The first amino acid residue affected by the insertions in both novel isoforms is Tyr-760, a residue that may play a crucial role in intracellular signaling through stimulation of the phosphatidylinositol-biphosphate pathway.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10791918     DOI: 10.1080/713803466

Source DB:  PubMed          Journal:  IUBMB Life        ISSN: 1521-6543            Impact factor:   3.885


  3 in total

1.  Loss of heterozygosity and DNA methylation affect germline fibroblast growth factor receptor 4 polymorphism to direct allelic selection in breast cancer.

Authors:  Xuegong Zhu; Lei Zheng; Sylvia L Asa; Shereen Ezzat
Journal:  Am J Pathol       Date:  2010-10-29       Impact factor: 4.307

2.  FGFR4 and its novel splice form in myogenic cells: Interplay of glycosylation and tyrosine phosphorylation.

Authors:  Boguslaw A Kwiatkowski; Irina Kirillova; Robert E Richard; David Israeli; Zipora Yablonka-Reuveni
Journal:  J Cell Physiol       Date:  2008-06       Impact factor: 6.384

3.  Targeted expression of a human pituitary tumor-derived isoform of FGF receptor-4 recapitulates pituitary tumorigenesis.

Authors:  Shereen Ezzat; Lei Zheng; Xian-Feng Zhu; Gillian E Wu; Sylvia L Asa
Journal:  J Clin Invest       Date:  2002-01       Impact factor: 14.808

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.